IMNM Q1 2024 Earnings — Immunome, Inc. Revenue & Financial Results | Market Cap Arena

IMNMImmunome, Inc.

$2B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-56.5% YoY

Gross Profit

$1M100.0% margin

Operating Income

-$132M-12857.0% margin

Net Income

-$129M-12584.3% margin

EPS (Diluted)

$-12.56

QoQ Revenue Growth

-73.1%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$13M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$320M

Total Liabilities

$34M

Stockholders' Equity

$286M

Cash & Equivalents

$270M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$2M	-56.5%
Gross Profit	$1M	-$2M	+166.4%
Operating Income	-$132M	-$4M	-2859.0%
Net Income	-$129M	-$4M	-2932.6%